How This Top 2% Biotech Overcame Two Obstacles And Doubled In A Month

has shucked off two high-profile setbacks, leading CYTK stock to double over a month as it looks to take on Big Pharma behemoth Bristol Myers Squibb (BMY) in heart disease treatment. Bristol Myers and Squibb are working to treat obstructive hypertrophic cardiomyopathy, or HCM, a genetic mutation…#bristolmyerssquibb #bmy #bristolmyers #squibb #hcm #cytokinetics #ubs #ashwaniverma #nvs #robertblum
Source: Reuters: Health - Category: Consumer Health News Source Type: news